PGM5 and nonpapillary renal cell carcinoma: A clinical study revealed that CCRCC patients with lower PGM5-AS1 expressions had substantially shorter overall survival (OS) and disease-free survival (DFS) than patients with higher PGM5-AS1 expressions.